{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:09:26Z","timestamp":1761498566547,"version":"build-2065373602"},"reference-count":72,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.beha.2020.101147","type":"journal-article","created":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T02:04:21Z","timestamp":1579226661000},"page":"101147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["MDS\/MPN-RS-T justified inclusion as a unique disease entity?"],"prefix":"10.1016","volume":"33","author":[{"given":"Guillermo","family":"Montalban-Bravo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.beha.2020.101147_bib1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/ajh.25397","article-title":"Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: \"2019 update on diagnosis, risk-stratification, and management\"","volume":"94","author":"Patnaik","year":"2019","journal-title":"Am J Hematol"},{"issue":"20","key":"10.1016\/j.beha.2020.101147_bib2","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2020.101147_bib3","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/j.1365-2141.2008.07526.x","article-title":"Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T) a necessary or useful diagnostic category?","volume":"144","author":"Wardrop","year":"2009","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.beha.2020.101147_bib4","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2020.101147_bib5","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1038\/sj.leu.2404373","article-title":"The JAK2 V617F mutation is rare in RARS but common in RARS-T","volume":"20","author":"Ceesay","year":"2006","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.beha.2020.101147_bib6","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3892\/ol.2014.2754","article-title":"An MPL W515L mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis: a case report","volume":"9","author":"Hao","year":"2015","journal-title":"Oncol Lett"},{"issue":"2","key":"10.1016\/j.beha.2020.101147_bib7","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood-2015-03-633537","article-title":"SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts","volume":"126","author":"Malcovati","year":"2015","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2020.101147_bib8","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMcp1816082","article-title":"Essential thrombocythemia","volume":"381","author":"Tefferi","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.beha.2020.101147_bib9","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/ajh.24332","article-title":"Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing","volume":"91","author":"Patnaik","year":"2016","journal-title":"Am J Hematol"},{"issue":"7367","key":"10.1016\/j.beha.2020.101147_bib10","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","article-title":"Frequent pathway mutations of splicing machinery in myelodysplasia","volume":"478","author":"Yoshida","year":"2011","journal-title":"Nature"},{"issue":"24","key":"10.1016\/j.beha.2020.101147_bib11","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.1182\/blood-2011-09-377275","article-title":"Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic\/myeloproliferative neoplasms","volume":"118","author":"Malcovati","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101147_bib12","doi-asserted-by":"crossref","first-page":"10004","DOI":"10.1038\/ncomms10004","article-title":"SF3B1 mutant MDS-initiating cells may arise from the haematopoietic stem cell compartment","volume":"6","author":"Mian","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.beha.2020.101147_bib13","first-page":"205318","article-title":"An active isodicentric x chromosome in a case of refractory anaemia with ring sideroblasts associated with marked thrombocytosis","volume":"2014","author":"Morales Camacho","year":"2014","journal-title":"Case Rep Genet"},{"issue":"7","key":"10.1016\/j.beha.2020.101147_bib14","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1182\/blood-2017-03-776070","article-title":"SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells","volume":"130","author":"Mortera-Blanco","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2020.101147_bib15","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/leu.2016.251","article-title":"Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts","volume":"31","author":"Mupo","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.beha.2020.101147_bib16","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ccell.2016.08.006","article-title":"Physiologic expression of Sf3b1(K700E) causes impaired erythropoiesis, aberrant splicing, and sensitivity to therapeutic spliceosome modulation","volume":"30","author":"Obeng","year":"2016","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.beha.2020.101147_bib17","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1038\/leu.2016.149","article-title":"Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes","volume":"30","author":"Dolatshad","year":"2016","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.beha.2020.101147_bib18","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1182\/blood-2018-04-843771","article-title":"Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes\/pathways and clinical associations","volume":"132","author":"Pellagatti","year":"2018","journal-title":"Blood"},{"issue":"500","key":"10.1016\/j.beha.2020.101147_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav5467","article-title":"A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome","volume":"11","author":"Bondu","year":"2019","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.beha.2020.101147_bib20","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41408-018-0051-1","article-title":"Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts","volume":"8","author":"Mangaonkar","year":"2018","journal-title":"Blood Canc J"},{"issue":"1","key":"10.1016\/j.beha.2020.101147_bib21","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1111\/bjh.16146","article-title":"JAK2 exon 12 mutation in myelodysplastic\/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: not an exclusive mutation to polycythaemia vera","volume":"187","author":"Inano","year":"2019","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.beha.2020.101147_bib22","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s12185-008-0169-1","article-title":"Refractory anemia with ringed sideroblasts associated with thrombocytosis: comparative analysis of marked with non-marked thrombocytosis, and relationship with JAK2 V617F mutational status","volume":"88","author":"Raya","year":"2008","journal-title":"Int J Hematol"},{"issue":"1","key":"10.1016\/j.beha.2020.101147_bib23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3960\/jslrt.18037","article-title":"Myelodysplastic\/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS\/MPN with RS-T) complicated by hyperleukocytosis and gene analysis in relation to leukocytosis","volume":"59","author":"Aoyama","year":"2019","journal-title":"J Clin Exp Hematop"},{"issue":"3","key":"10.1016\/j.beha.2020.101147_bib24","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1182\/blood-2007-11-121608","article-title":"JAK2 V617F and ringed sideroblasts: not necessarily RARS-T","volume":"111","author":"Steensma","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2020.101147_bib25","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/leu.2014.8","article-title":"Myelodysplastic\/myeloproliferative neoplasms, unclassifiable (MDS\/MPN, U): natural history and clinical outcome by treatment strategy","volume":"28","author":"DiNardo","year":"2014","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.beha.2020.101147_bib26","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood-2014-02-553800","article-title":"Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic\/myeloproliferative neoplasms","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2020.101147_bib27","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2020.101147_bib28","doi-asserted-by":"crossref","first-page":"9714","DOI":"10.18632\/oncotarget.23882","article-title":"Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic\/myeloproliferative neoplasms","volume":"9","author":"Montalban-Bravo","year":"2018","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.beha.2020.101147_bib29","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.beha.2020.101147_bib30","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/PAS.0000000000001058","article-title":"Chronic myelomonocytic leukemia with fibrosis is a distinct disease subset with myeloproliferative features and frequent JAK2 p.V617F mutations","volume":"42","author":"Gur","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.beha.2020.101147_bib31","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1080\/1042819021000037903","article-title":"Sideroblastic anaemia with reactive thrombocytosis versus myelodysplastic\/myeloproliferative disease","volume":"44","author":"Perez Sanchez","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.beha.2020.101147_bib32","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1309\/AJCPT0B6VEQPRCOA","article-title":"Refractory anemia with ring sideroblasts associated with marked thrombocytosis: a mixed group exhibiting a spectrum of morphologic findings","volume":"135","author":"Gurevich","year":"2011","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"10.1016\/j.beha.2020.101147_bib33","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","article-title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv"},{"issue":"17","key":"10.1016\/j.beha.2020.101147_bib34","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1182\/blood-2009-05-222331","article-title":"Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis","volume":"114","author":"Malcovati","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2020.101147_bib35","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.3324\/haematol.2014.119032","article-title":"Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations","volume":"100","author":"Jeromin","year":"2015","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.beha.2020.101147_bib36","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1038\/leu.2014.49","article-title":"Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis","volume":"28","author":"Broseus","year":"2014","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.beha.2020.101147_bib37","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3324\/haematol.2011.053918","article-title":"Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis","volume":"97","author":"Broseus","year":"2012","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.beha.2020.101147_bib38","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/hon.2670","article-title":"Comparison between thrombotic risk scores in essential thrombocythemia and survival implications","volume":"37","author":"Santoro","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.beha.2020.101147_bib39","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719870052","article-title":"Updates in the management of polycythemia vera and essential thrombocythemia","volume":"10","author":"Bose","year":"2019","journal-title":"Ther Adv Hematol"},{"issue":"7","key":"10.1016\/j.beha.2020.101147_bib40","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1080\/10428194.2016.1246725","article-title":"Negative impact on clinical outcome of the mutational co-occurrence of SF3B1 and DNMT3A in refractory anemia with ring sideroblasts (RARS)","volume":"58","author":"Martin","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.beha.2020.101147_bib41","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1038\/leu.2013.120","article-title":"Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis","volume":"27","author":"Broseus","year":"2013","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.beha.2020.101147_bib42","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00277-008-0450-7","article-title":"Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis","volume":"87","author":"Moyo","year":"2008","journal-title":"Ann Hematol"},{"issue":"21","key":"10.1016\/j.beha.2020.101147_bib43","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1200\/JCO.2007.15.4906","article-title":"Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome","volume":"26","author":"Jadersten","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2020.101147_bib44","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1182\/blood-2004-10-3872","article-title":"Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF","volume":"106","author":"Jadersten","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2020.101147_bib45","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1182\/blood-2007-06-096370","article-title":"Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience","volume":"111","author":"Park","year":"2008","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2020.101147_bib46","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1038\/leu.2017.192","article-title":"A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes","volume":"31","author":"Platzbecker","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2020.101147_bib47","first-page":"37","article-title":"Lenalidomide induced durable remission in a patient with MDS\/MPN-with ring sideroblasts and thrombocytosis with associated 5q- syndrome","volume":"10","author":"Alshaban","year":"2018","journal-title":"Leuk Res Rep"},{"issue":"2","key":"10.1016\/j.beha.2020.101147_bib48","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1182\/blood-2010-01-263087","article-title":"Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis","volume":"116","author":"Huls","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2020.101147_bib49","doi-asserted-by":"crossref","first-page":"E27","DOI":"10.1002\/ajh.24952","article-title":"Lenalidomide therapy in patients with myelodysplastic syndrome\/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS\/MPN-RS-T)","volume":"93","author":"Nicolosi","year":"2018","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.beha.2020.101147_bib50","doi-asserted-by":"crossref","first-page":"6592","DOI":"10.4081\/hr.2016.6592","article-title":"Treatment of refractory anemia with ring sideroblasts associated with marked thrombocytosis with lenalidomide in a patient testing negative for 5q deletion and JAK2 V617F and MPL W515K\/L mutations","volume":"8","author":"Keen","year":"2016","journal-title":"Hematol Rep"},{"key":"10.1016\/j.beha.2020.101147_bib51","first-page":"718480","article-title":"Refractory anemia with ring sideroblasts associated with marked thrombocytosis complicated by massive splenomegaly treated with lenalidomide resulting in resolution of splenomegaly but severe and prolonged pancytopenia","volume":"2013","author":"Taylor","year":"2013","journal-title":"Case Rep Hematol"},{"issue":"5","key":"10.1016\/j.beha.2020.101147_bib52","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/s41375-019-0420-1","article-title":"The role of TGFbeta in hematopoiesis and myeloid disorders","volume":"33","author":"Bataller","year":"2019","journal-title":"Leukemia"},{"issue":"Supplement_1","key":"10.1016\/j.beha.2020.101147_bib53","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1182\/blood-2019-123064","volume":"134","author":"Fenaux","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2020.101147_bib54","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S1470-2045(17)30615-0","article-title":"Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study","volume":"18","author":"Platzbecker","year":"2017","journal-title":"Lancet Oncol"},{"issue":"Supplement_1","key":"10.1016\/j.beha.2020.101147_bib55","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1182\/blood-2019-123048","volume":"134","author":"Garcia-Manero","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2020.101147_bib56","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1182\/blood-2018-163","article-title":"The believe trial: results of a phase 3, randomized, double-blind, placebo-controlled study of luspatercept in adult beta-thalassemia patients who require regular red blood cell (RBC) transfusions","volume":"132","author":"Cappellini","year":"2018","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.beha.2020.101147_bib57","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1182\/blood-2019-122546","article-title":"A phase 2 study of luspatercept in patients with myelofibrosis-associated anemia","volume":"134","author":"Gerds","year":"2019","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.beha.2020.101147_bib58","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1002\/cncr.31550","article-title":"Iron overload in patients with myelodysplastic syndromes: an updated overview","volume":"124","author":"Moukalled","year":"2018","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.beha.2020.101147_bib59","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41419-018-0552-7","article-title":"Iron overload promotes mitochondrial fragmentation in mesenchymal stromal cells from myelodysplastic syndrome patients through activation of the AMPK\/MFF\/Drp1 pathway","volume":"9","author":"Zheng","year":"2018","journal-title":"Cell Death Dis"},{"issue":"3-S","key":"10.1016\/j.beha.2020.101147_bib60","first-page":"18","article-title":"The impact of iron overload in patients with acute leukemia and myelodysplastic syndrome on hepatic and endocrine functions","volume":"89","author":"Yassin","year":"2018","journal-title":"Acta Biomed"},{"issue":"62","key":"10.1016\/j.beha.2020.101147_bib61","doi-asserted-by":"crossref","first-page":"105510","DOI":"10.18632\/oncotarget.22299","article-title":"Reactive oxygen species levels control NF-kappaB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes","volume":"8","author":"Meunier","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.beha.2020.101147_bib62","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00277-018-3539-7","article-title":"Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes","volume":"98","author":"Zeidan","year":"2019","journal-title":"Ann Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2020.101147_bib63","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1182\/blood-2018-99-111134","article-title":"Safety and efficacy, including event-free survival, of deferasirox versus placebo in iron-overloaded patients with low- and int-1-risk myelodysplastic syndromes (MDS): outcomes from the randomized, double-blind telesto study","volume":"132","author":"Angelucci","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101147_bib64","first-page":"253294","article-title":"Durable red blood cell transfusion independence in a patient with an MDS\/MPN overlap syndrome following discontinuation of iron chelation therapy","volume":"2015","author":"Kochhar","year":"2015","journal-title":"Case Rep Hematol"},{"key":"10.1016\/j.beha.2020.101147_bib65","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2017-06-788497","article-title":"A randomized phase II study of low-dose decitabine versus low-dose azacitidine in lower risk MDS and MDS\/MPN","author":"Jabbour","year":"2017","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.beha.2020.101147_bib66","doi-asserted-by":"crossref","first-page":"4748","DOI":"10.1182\/blood-2019-128821","article-title":"Clinical effectiveness of hypomethylating agents (HMAs) and lenalidomide (len) in older patients (pts) with refractory anemia with ring sideroblasts: a large population-based study in the United States (US)","volume":"134","author":"Wang","year":"2019","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2020.101147_bib67","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1038\/leu.2016.216","article-title":"Vascular events and risk factors for thrombosis in refractory anemia with ring sideroblasts and thrombocytosis","volume":"30","author":"Patnaik","year":"2016","journal-title":"Leukemia"},{"issue":"16","key":"10.1016\/j.beha.2020.101147_bib68","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1182\/blood-2012-05-430876","article-title":"SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes","volume":"120","author":"Visconte","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2020.101147_bib69","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/ajh.23895","article-title":"Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management","volume":"90","author":"Tefferi","year":"2015","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.beha.2020.101147_bib70","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","article-title":"Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia","volume":"116","author":"Alvarez-Larran","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2020.101147_bib71","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1055\/s-2006-949664","article-title":"The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera","volume":"32","author":"Michiels","year":"2006","journal-title":"Semin Thromb Hemost"},{"issue":"6","key":"10.1016\/j.beha.2020.101147_bib72","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000150","article-title":"Diagnosis and treatment of chronic myelomonocytic leukemias in adults: recommendations from the European Hematology association and the European LeukemiaNet","volume":"2","author":"Itzykson","year":"2018","journal-title":"Hemasphere"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692620300086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692620300086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:05:44Z","timestamp":1761498344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692620300086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":72,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S1521692620300086"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2020.101147","relation":{},"ISSN":["1521-6926"],"issn-type":[{"type":"print","value":"1521-6926"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MDS\/MPN-RS-T justified inclusion as a unique disease entity?","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2020.101147","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101147"}}